Literature DB >> 8241973

Systemic lupus erythematosus-related autoantibody production in mice is determined by bone marrow-derived cells.

M Levite1, H Zinger, E Mozes, Y Reisner.   

Abstract

Experimental systemic lupus erythematosus (SLE) can be induced in mice by immunization with either a human monoclonal anti-DNA antibody bearing the 16/6 idiotype (16/6 Id) or with a mouse monoclonal anti-idiotypic antibody specific for the 16/6 Id. Susceptibility to the induction of experimental SLE is genetically determined but is not linked to the MHC. In the present study we tested the susceptibility of BM chimeras of different donor-host combinations to the induction of SLE and found that high levels of anti-16/6 Id and anti-ssDNA antibodies were induced in BALB/c-->C57BL/6, BALB/c-->BALB/c and normal BALB/c mice as opposed to C57BL/6-->BALB/c chimeras and normal C57BL/6 mice. The low levels of the anti-16/6 Id and anti-ssDNA antibodies produced by C57BL/6-->BALB/c chimeras immunized with the 16/6 fully allogeneic BMT as such chimeras were shown to produce high levels of antibodies to a T cell-dependent antigen (the synthetic polypeptide (Phe,G)-A--L). These results demonstrate that the production of SLE-related autoantibodies is controlled by donor-type BM derived cells and not by host-type cells in the thymic stroma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241973

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Transplantation with allogenic bone marrow from a donor with systemic lupus erythematosus (SLE): successful outcome in the recipient and induction of an SLE flare in the donor.

Authors:  G Sturfelt; S Lenhoff; B Sallerfors; O Nived; L Truedsson; A G Sjöholm
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

Review 2.  Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis.

Authors:  Sendhilnathan Ramalingam; Ankoor Shah
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-24       Impact factor: 4.806

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.